NLRP2 is highly expressed in a mouse model of ischemic stroke.
Nucleotide binding oligomerization domain (NOD)-like receptors (NLRs) are a class of cytoplasmic pattern-recognition receptors with a major role in innate immunity. Fourteen of the twenty-two human NLRs contain a pyrin domain and form the NLRP subfamily (NLRPs). Among NLRPs, NLRP2 is less well-understood in aspects of distribution and functions, especially in central nervous system (CNS). This study was the first to explore the expression of NLRP2 in central nervous system both under normal conditions and in ischemic stroke models. We found NLRP2 protein had a basal level of expression in CNS, mainly in astrocytes and was significantly elevated in ischemic brains in vivo or oxygen-glucose deprivation-treated cells in vitro. And silencing of NLRP2 genes could reduce the apoptotic rate of oxygen-glucose deprivation-treated cells. Thus high expression of NLRP2, especially in astrocytes, may play important roles in the pathophysiological process of ischemic stroke and has potential clinical value for the treatment of ischemic stroke.
Department of Pharmacology, Shandong University School of Medicine, Jinan, Shandong, 250012 PR China.
Xia
X
Sun
Department of Pharmacology, Shandong University School of Medicine, Jinan, Shandong, 250012 PR China.
Xiao
X
Song
Department of Gastrointestinal Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021 PR China.
Li
L
Zhang
Department of Pharmacology, Shandong University School of Medicine, Jinan, Shandong, 250012 PR China.
Jian
J
Sun
Department of Pharmacology, Shandong University School of Medicine, Jinan, Shandong, 250012 PR China.
Xinbing
X
Wei
Department of Dermatology, The Second Affiliated Hospital of Shandong University, Jinan, Shandong, 250033 PR China.
Liya
L
Meng
Department of Pharmacology, Shandong University School of Medicine, Jinan, Shandong, 250012 PR China. Electronic address: anjie@sdu.edu.cn.
Jie
J
An
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D051017:Apoptosis Regulatory Proteins; D001253:Astrocytes / Q000378:metabolism* / Q000473:pathology; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D020868:Gene Silencing; D005947:Glucose / Q000172:deficiency; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D058990:Molecular Targeted Therapy; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D020521:Stroke / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D015854:Up-Regulation
D048868:Adaptor Proteins, Signal Transducing; D051017:Apoptosis Regulatory Proteins; C572552:Nlrp2 protein, mouse; D011506:Proteins; D034741:RNA, Small Interfering; D005947:Glucose
Astrocyte; Inflammasome; Ischemic stroke; NLRP2